<DOC>
	<DOCNO>NCT02143076</DOCNO>
	<brief_summary>Youth diagnose sickle cell disease ( SCD ) may difficulty take medication prescribe ( adherence ) . Hydroxyurea ( HU ) one medication youth may take help manage SCD . Electronic adherence monitoring widely consider gold standard objective adherence measurement . These monitor provide continuous , real-time record medication adherence reveal problematic behavior pattern , include underdosing , overdose , delayed dosing , `` drug holiday '' ( i.e . individual take medication specify interval time ) , `` white coat '' adherence ( i.e. , pattern drug adherence function time individual display good adherence immediately clinic attendance worsen adherence period ) . Overall , electronic adherence measure consider valid , reliable , accurate , clear advantage pharmacy refill record , physician estimate self-report measure . Currently , one electronic measure capable monitoring medication pill liquid form manufacture : WisePill WiseBag . While data limit regard validity reliability , preliminary data support use Wise technology measure adherence medication . The current study determine Wise device 's ability feasibly measure adherence liquid solid form HU medication pediatric SCD population .</brief_summary>
	<brief_title>Medication Adherence Youth With Sickle Cell Disease ( SCD )</brief_title>
	<detailed_description>This research study evaluate HU adherence use electronic storage device ( Wise device ) compare caregiver report , youth report , lab value , pill-count adherence measure . The investigator ask participant store medication Wise device answer question use device normal clinical care visit . PRIMARY OBJECTIVE - To examine feasibility WISE device estimate ) rate consent study , b ) rate WISE device use , c ) rate WISE device failure , ) perceive acceptability use WISE device , report caregiver youth . SECONDARY OBJECTIVE - To estimate association HU adherence measure Wise device , ) caregiver-report , b ) youth-report , c ) lab value , ) pill-count , e ) Medication Possession Ratio ( MPR ) adherence measure . Evaluation study outcome stratify age group : ( 1 ) infants/toddlers , age 0-7 year ; ( 2 ) school age , age 8-12 year ; ( 3 ) teen , age 13-17 year . At study enrollment , participant ask complete one questionnaire receive instruction use Wise device . They ask use Wise device follow two month . A study team member contact participant phone within seven day study enrollment monitor participant use Wise device answer question . Participants ask return Wise device two month normal clinic care visit . At visit , participant ask complete two questionnaire , part standard clinical care , pill count/bottle weight complete pharmacy .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Confirmed diagnosis SCD ( genotype ) . Less 18 year age time study entry . Currently follow St. Jude Children 's Research Hospital ( SJCRH ) SCD clinic . Stable HU dose prescribed ( pill liquid formulation ) â‰¥ 6 month without documented hematological toxicity ( exclude dose adjustment weight gain ) . Lives primary caregiver . Anticipated return clinic propose 4week 8week interval . Primary caregiver and/or youth unable understand English and/or youth cognitively intact ( know IQ &lt; 70 ) study questionnaire understood complete . Any condition chronic illness opinion PI CoI make participation study illadvised .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Medication Adherence</keyword>
	<keyword>Hydroxyurea</keyword>
</DOC>